ch.oddb.org
 
Analyses | Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
 You are at - Home - Information for professionals for IMBRUVICA®
Information for professionals for IMBRUVICA®:Janssen-Cilag AG
Complete information for professionalsDDDÄnderungen anzeigenPrint
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information
L01XE27 - IbrutinibATC-DDD Version 2016. Source: WHO
L - Antineoplastic and Immunomodulating Agents

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L01 - Antineoplastic Agents

Combination products are classified in L01XY - Combinations of antineoplastic agents.
Detoxifying agents used in connection with high dose treatment of antineoplastic agents are classified in V03AF (e.g. calcium folinate)

No DDDs have been established because of highly individualised use and wide dosage ranges. The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.
The consumption of the antineoplastic agents is in some countries measured in grams. This is recommended as a method to be used internationally for these particular agents.

L01X - Other Antineoplastic Agents

This group comprises antineoplastic preparations which cannot be classified in the preceding groups.

L01XE - Protein Kinase Inhibitors
 
L01XE27 - Ibrutinib
LGPL2017 ywesee.com, Commit-ID
Settings | Help | FAQ | Login | Contact | Home